uniQure price target raised to $24 from $20 at RBC Capital

RBC Capital analyst Luca Issi raised the firm’s price target on uniQure (QURE) to $24 from $20 and keeps an Outperform rating on the shares as part of a broader research note previewing Q4 and 2025 earnings in the Biotech sector. Q4 should should come in generally solid across the firm’s large and mid-cap commercial stage companies, helped by seasonal tailwinds, though 2025 expectations may be seeing more optimism than necessarily warranted with a number of launches already baked into numbers and durability of certain core franchises that could challenge certain setups, the analyst tells investors in a research note. RBC adds that it continues to like the set-up for uniQure despite the recent run after the company aligned with the FDA on a potential path to accelerated approval for Huntington’s disease as well as the company not having near-term capital needs.